Literature DB >> 21966123

Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice.

Upma Bagai1, Anil Pawar, Vineet Kumar.   

Abstract

Progress towards a vaccine against malaria is advancing rapidly with several candidate antigens being tested for their safety and efficacy. In present investigation, two polypeptides (43 and 48 kDa) of Plasmodium berghei (NK-65) were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Immunogenicity and protective efficacy of both these polypeptides formulated in saponin has been compared in Balb/c mice against challenge infection with P. berghei. Antibody responses were evaluated by indirect fluorescent antibody test and enzyme-linked immunosorbent assay. Merozoite invasion inhibition assay and challenge infections revealed that 48 kDa antigen is better immunogen as compared to 43 kDa and provide better protection against rodent malaria infection.

Entities:  

Keywords:  43 kDa; 48 kDa; Antibody; Immunity; Malaria; Plasmodium; Vaccine

Year:  2010        PMID: 21966123      PMCID: PMC3081735          DOI: 10.1007/s12639-010-0012-5

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  32 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Fusogenic potential of prokaryotic membrane lipids. Implication in vaccine development.

Authors:  N Ahmad; A K Masood; M Owais
Journal:  Eur J Biochem       Date:  2001-11

3.  Properties of protective malarial antibody.

Authors:  S Cohen; G A Butcher
Journal:  Immunology       Date:  1970-08       Impact factor: 7.397

4.  Host cell specificity and schizogony of Plasmodium berghei under different in vitro conditions.

Authors:  C J Janse; E G Boorsma; J Ramesar; M J Grobbee; B Mons
Journal:  Int J Parasitol       Date:  1989-08       Impact factor: 3.981

5.  A reticulocyte-binding protein complex of Plasmodium vivax merozoites.

Authors:  M R Galinski; C C Medina; P Ingravallo; J W Barnwell
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

Review 6.  The pathogenic basis of malaria.

Authors:  Louis H Miller; Dror I Baruch; Kevin Marsh; Ogobara K Doumbo
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

7.  Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine.

Authors:  S L Hoffman; M Sedegah; R C Hedstrom
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

8.  Malaria (Plasmodium knowlesi) merozoites: immunity and the surface coat.

Authors:  L H Miller; M Aikawa; J A Dvorak
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

Review 9.  Adjuvants for human vaccines--current status, problems and future prospects.

Authors:  R K Gupta; G R Siber
Journal:  Vaccine       Date:  1995-10       Impact factor: 3.641

Review 10.  Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.

Authors:  Manuel E Patarroyo; Manuel A Patarroyo
Journal:  Acc Chem Res       Date:  2008-02-12       Impact factor: 22.384

View more
  2 in total

1.  Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer.

Authors:  Mingjun Xiang; Wei Zhou; Dandan Gao; Xiansong Fang; Qian Liu
Journal:  Int J Mol Sci       Date:  2012-12-07       Impact factor: 5.923

2.  The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Authors:  Anna L Goodman; Emily K Forbes; Andrew R Williams; Alexander D Douglas; Simone C de Cassan; Karolis Bauza; Sumi Biswas; Matthew D J Dicks; David Llewellyn; Anne C Moore; Chris J Janse; Blandine M Franke-Fayard; Sarah C Gilbert; Adrian V S Hill; Richard J Pleass; Simon J Draper
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.